Pirbuterol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For other uses, see Maxair (disambiguation).
Pirbuterol
Pirbuterol.svg
Clinical data
Trade names Maxair
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a601096
Pregnancy
category
  • C
Routes of
administration
Inhalational (MDI)
ATC code R03AC08 (WHO) R03CC07 (WHO)
Legal status
Legal status
Identifiers
CAS Number 38029-10-6 N
PubChem (CID) 4845
IUPHAR/BPS 7272
DrugBank DB01291 YesY
ChemSpider 4679 YesY
UNII OG645J8RVW YesY
KEGG D08387 N
ChEMBL CHEMBL1094966 YesY
Chemical and physical data
Formula C12H20N2O3
Molar mass 240.30 g/mol
300.3 g/mol (acetate)
3D model (Jmol) Interactive image
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler (Maxair Autohaler).

Clinical use[edit]

Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[1][2]

Mode of action[edit]

Further information: Beta2-adrenergic agonist

Pharmacokinetics[edit]

After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[1]

Adverse effects[edit]

Further information: Beta2-adrenergic agonist

References[edit]

  1. ^ a b "Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Retrieved 7 March 2016. 
  2. ^ Bianchi, Marina; Clavenna, Antonio; Bonati, Maurizio (2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period". European Journal of Clinical Pharmacology. 66 (9): 929–936. doi:10.1007/s00228-010-0845-y. ISSN 0031-6970. 

External links[edit]